Successful treatment of a LifeSite Hemodialysis Access System pocket infection with large-volume kanamycin solution irrigation.
Bridge devices-dialysis catheters and subcutaneous access devices-play a critical role in increasing the placement of arteriovenous (AV) fistulas by providing hemodialysis vascular access while AV fistulas mature. The LifeSite Hemodialysis Access System (Vasca Inc, Tewskburg, MA), a fully implantable, subcutaneous dual valve access system, has been shown to have lower complication rates, higher blood flow rates, and better long-term device survival than conventional tunneled hemodialysis catheters, indicating it may better meet the requirements for optimally bridging to a fistula. This case study of a 48-year-old black man undergoing chronic hemodialysis for renal failure because of insulin-dependent diabetes describes a simple approach for resolving localized pocket infections associated with the LifeSite System by drip irrigation of the valves and tissue pockets with an antibiotic solution. Eight weeks after implantation of the LifeSite System, the patient exhibited symptoms of infection of the lateral LifeSite valve tissue pocket, which on culture was shown to be caused by Staphylococcus aureus. Flushing the LifeSite valve and tissue pocket with a large volume of kanamycin solution, in conjunction with intravenous vancomycin and routine irrigation of the valve with isopropyl alcohol, resolved the infection after 1 treatment. The LifeSite System successfully bridged the patient to a transposed basilic vein fistula created through a 2-stage surgical procedure. The LifeSite System provided uninterrupted access for hemodialysis over a period of 6 months while the fistula matured. The LifeSite System should allow surgeons to attempt fistula construction in more patients, including diabetics, access-challenged patients, and patients with small vessels, who may benefit from a nontraditional surgical approach toward fistula creation.
Ross
John R
JR
Department of General Surgery, Bamberg County Hospital, Bamberg, SC 29003, USA.
D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D002408:Catheters, Indwelling / Q000009:adverse effects*; D006801:Humans; D007612:Kanamycin / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D012074:Remission Induction; D006435:Renal Dialysis; D013203:Staphylococcal Infections / Q000188:drug therapy* / Q000209:etiology; D007507:Therapeutic Irrigation
D000900:Anti-Bacterial Agents; D007612:Kanamycin